Rockwell Medical (RMTI) Cost of Revenue (2010 - 2026)

Rockwell Medical's Cost of Revenue history runs 17 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• Quarterly Cost of Revenue fell 9.03% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.1 million (down 30.07% YoY) and the FY2025 annual result came in at $57.6 million, down 31.48% from the prior year.
• Cost of Revenue was $14.4 million for Q1 2026 at Rockwell Medical, roughly flat from $14.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $22.1 million in Q3 2024 and bottomed at $13.6 million in Q2 2025.
• A 5-year average of $17.6 million and a median of $17.0 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue grew 24.84% — and 2025, when it tumbled 38.15%.
• Rockwell Medical's Cost of Revenue stood at $17.0 million in 2022, then climbed by 13.26% to $19.2 million in 2023, then rose by 9.42% to $21.0 million in 2024, then plunged by 31.22% to $14.5 million in 2025, then retreated by 0.2% to $14.4 million in 2026.
• Business Quant data shows RMTI's Cost of Revenue at $14.4 million in Q1 2026, $14.5 million in Q4 2025, and $13.7 million in Q3 2025.